EGFR and non-small cell lung carcinoma: In the AURA study, which evaluated the safety and efficacy of osimertinib at doses of 20–240 mg once daily in patients with NSCLC harboring EGFR mutations and disease progression after previous treatment with EGFR-TKIs, the response rate was similar at doses of 20 mg, 40 mg, and 80 mg daily28.